Immunome INC Schedule 13G passive stakes

Sirenia Capital Management LP and Alex Silverstein have reported beneficial ownership of 4.3% of Immunome Inc.'s common stock as of June 30, 2026.

Redmile Group, LLC and Jeremy C. Green have filed a Schedule 13G reporting a 4.9% beneficial ownership stake in Immunome, Inc.

T. Rowe Price Investment Management, Inc. has reported a beneficial ownership of 14.5% in Immunome Inc. as of March 31, 2026.

Sirenia Capital Management LP and Alex Silverstein have jointly filed a Schedule 13G, reporting beneficial ownership of 6.1% of Immunome Inc.'s common stock as of March 31, 2026.

The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in Immunome Inc. following an internal corporate realignment.

T. Rowe Price Investment Management, Inc. has disclosed a 12.2% beneficial ownership stake in IMMUNOME INC, holding over 10.6 million shares.

FMR LLC and Abigail P. Johnson reported beneficial ownership of 15.0% of IMMUNOME INC's common stock as of September 30, 2025.

FMR LLC and Abigail P. Johnson have disclosed a 7.1% beneficial ownership stake in IMMUNOME INC's common stock as of June 30, 2025.

The Vanguard Group has reported a 5.2% beneficial ownership stake in Immunome Inc., holding 4,524,952 shares of common stock as of June 30, 2025.

Investment firm Redmile Group, LLC, along with its principal Jeremy C. Green, has disclosed a passive beneficial ownership of 6.2% in Immunome, Inc., totaling 5,361,187 shares of common stock.

EcoR1 Capital, LLC and its affiliates have filed an amendment to their Schedule 13G, indicating a reduction in their beneficial ownership of Immunome Inc. common stock to 4.7%, falling below the 5% reporting threshold.

Janus Henderson Group PLC has filed an amended Schedule 13G, disclosing a 2.2% beneficial ownership stake in IMMUNOME INC, held for investment purposes in the ordinary course of business.

FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, disclosing a reduction in their beneficial ownership stake in IMMUNOME INC to 4.5% as of March 31, 2025.

Janus Henderson Group plc has filed an amended Schedule 13G, disclosing a 5.5% beneficial ownership stake in IMMUNOME INC as of December 31, 2024.

Point72 Asset Management, L.P., along with Point72 Capital Advisors, Inc. and Steven A. Cohen, has disclosed a passive beneficial ownership of 5.9% in Immunome Inc., totaling 4,887,110 shares.

The Vanguard Group has filed an amendment to its Schedule 13G, reporting a beneficial ownership of 4.81% in Immunome Inc.'s common stock as of December 31, 2024.